Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults
2017
Background. This study ({"type":"clinical-trial","attrs":{"text":"NCT02503202","term_id":"NCT02503202"}}NCT02503202) evaluated the safety of recombinant vesicular stomatitis virus–Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP).
Keywords:
-
Correction
-
Source
-
Cite
-
Save
11
References
52
Citations
NaN
KQI